Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fisher & Paykel HealthcareASX:FPH -0.27%88 Cash Ratio is 0.93 as of Mar. 2026, which is 45% above its 10-year median of 0.64. GuruFocus rates ASX:FPH with a GF Score™ of 88/100 and a GF Value™ of A$36.67 (Fairly Valued). The stock has 2 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 51.72% on this metric.
Fisher & Paykel Healthcare has a Cash Ratio of 0.93. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Fisher & Paykel Healthcare's Cash Ratio or its related term are showing as below:
ASX:FPH'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.64 Max: 0.95
Current: 0.93
During the past 13 years, Fisher & Paykel Healthcare's highest Cash Ratio was 0.95. The lowest was 0.21. And the median was 0.64.
ASX:FPH's Cash Ratio is ranked worse than 51.72% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 0.98
vs ASX:FPH: 0.93
Fisher & Paykel Healthcare (ASX:FPH) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Fisher & Paykel Healthcare Cash Ratio Related Terms
Fisher & Paykel Healthcare Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare Cash Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare (ASX:FPH) has a Cash Ratio of 0.93 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fisher & Paykel Healthcare and its competitors. This is 45% above median its historical median of 0.64. Over the past decade, Fisher & Paykel Healthcare's Cash Ratio has ranged from 0.21 to 0.95. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #435 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 51.7%.
Is Fisher & Paykel Healthcare's Cash Ratio too high?
Fisher & Paykel Healthcare's current Cash Ratio of 0.93 is 45% above median its 10-year median of 0.64. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 0.95. The Medical Devices & Instruments industry median Cash Ratio is 0.98. Fisher & Paykel Healthcare's value of 0.93 is 5.1% below this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #435 out of 841 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Fisher & Paykel Healthcare has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Cash Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #435 out of 841 companies for Cash Ratio. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median Cash Ratio is 0.98. Fisher & Paykel Healthcare's value of 0.93 is 5.1% below this benchmark. Historically, Fisher & Paykel Healthcare's own Cash Ratio has ranged from 0.21 to 0.95 over the past decade. While the company's 10-year median is 0.64 vs. the industry median of 0.98, Fisher & Paykel Healthcare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Medical Devices & Instruments company?
The median Cash Ratio among Medical Devices & Instruments companies is 0.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current Cash Ratio of 0.93 is 5.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Cash Ratio is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current Cash Ratio is 0.93, which is 45% above median its own 10-year median of 0.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Fairly Valued. The stock's GF Value™ is A$36.67, compared to a current price of A$33.22 — trading 9.4% below its estimated fair value. The current Cash Ratio is 0.93, which is 45% above median its 10-year median of 0.64 and 5.1% below the Medical Devices & Instruments industry median of 0.98. Fisher & Paykel Healthcare's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current Cash Ratio is 0.93 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$33.22 is trading 9.4% below its estimated GF Value™ of A$36.67.
GuruFocus considers Fisher & Paykel Healthcare to be Fairly Valued.
Key valuation signals for ASX:FPH:
Cash Ratio: 0.93 (45% above median its 10-year median of 0.64)
GF Value™: A$36.67 vs. price of A$33.22 (9.4% below fair value)
Industry Position: 5.1% below the Medical Devices & Instruments median (#435 of 841)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
88GF Score
Get the complete analysis for ASX:FPH
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
